Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-24-000169
Filing Date
2024-08-01
Accepted
2024-08-01 06:52:37
Documents
69
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20240630.htm   iXBRL 10-Q 1515416
2 EX-10.1 denali-biogensideletter.htm EX-10.1 47690
3 EX-31.1 exhibit311q22024.htm EX-31.1 9894
4 EX-31.2 exhibit312q22024.htm EX-31.2 9914
5 EX-32.1 exhibit321q22024.htm EX-32.1 5552
6 EX-32.2 exhibit322q22024.htm EX-32.2 5681
12 image.jpg GRAPHIC 6166
  Complete submission text file 0001714899-24-000169.txt   6616463

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240630.xsd EX-101.SCH 43446
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20240630_cal.xml EX-101.CAL 49681
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20240630_def.xml EX-101.DEF 217317
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240630_lab.xml EX-101.LAB 572435
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240630_pre.xml EX-101.PRE 399602
71 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240630_htm.xml XML 816506
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 241164127
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)